Navigation Links
First Boston Pharma, LLC Acquires NutraMax Products, Inc.
Date:5/13/2009

GLOUCESTER, Mass., May 13 /PRNewswire/ -- First Boston Pharma announces the acquisition of NutraMax, Products, Inc., a contract manufacturer of solid dose and soft chew pharmaceuticals and supplements. The company will now be known as First Boston Pharma, LLC.

Leading the First Boston Pharma organization is Mario Medri, one of the industry's foremost innovators in over-the-counter ("OTC") drugs and supplement formulations. With over 40 years of experience in the consumer packaging goods industry, Medri has developed a multitude of products in the OTC drug and supplements categories, as well as flavors, fragrances, confections, foods and cosmetics. He holds over 15 product and process patents. Medri's many contributions to the market include inventing soft chews as a vehicle for delivery of OTC drugs and supplements and developing new products and technologies for pectin/menthol cough drops, honey liquid center cough drops and liquid center throat lozenges.

"The acquisition by Mario and the First Boston Pharma Group will propel the company further and faster along the trajectory we are on, particularly with designer products for pharmaceuticals and supplement markets," says Rodney Plunkett, Executive Vice President of First Boston Pharma. "To have the industry's foremost innovator leading First Boston Pharma into the future is an exciting prospect for us and for our customers," adds Plunkett.

The acquisition of NutraMax by First Boston Pharma will provide the necessary resources for the company to pursue its strategy of innovation in the over-the-counter drugs and supplements categories. The company will drive its growth strategy though investment in additional R&D, and in unique production capabilities. "One of our key strategies is to move to a supply base integrity model, which gives our customers the differentiated products they need, when they want them," says Medri.

About First Boston Pharma, LLC:

First Boston Pharma, LLC is a contract manufacturer of solid dose, soft chew, liquid, tablet and chewing gum based pharmaceuticals and supplements servicing branded companies and retailer private label products. The company provides turnkey services to customers wishing to introduce new products from product ideation to R&D, product development to production. Headquartered in Gloucester, MA, First Boston Pharma has an additional facility in Brockton, MA. All facilities are FDA registered drug manufacturing sites, and also cGMP and DSHEA compliant. For more information, visit www.Firstbostonpharma.com

LINKS

Mario Medri mmedri@1stbp.com

Rodney Plunkett rplunkett@1stbp.com

First Boston Pharma, LLC www.firstbostonpharma.com


'/>"/>
SOURCE First Boston Pharma, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Super Lice Repelled by All-Natural Products First Ever Independent Study Shows
2. AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
3. China Medicine Announces First Quarter 2009 Results
4. Amilpar - Revenue Increases 13.4% and Medical Loss Ratio Falls in the First Quarter 2009
5. Pharmos Corporation Reports 2009 First Quarter Results
6. Pregis Announces First Quarter 2009 Financial Results
7. Access to care leads Americans priorities in first-ever public study of health value
8. Access to Care Leads Americans Priorities in First-Ever Public Study of Health Value
9. The Nielsen Company Launches First-Ever CLIO Healthcare Awards Acknowledging Creative Excellence in Healthcare Communications
10. Advanced Life Sciences Announces First Quarter 2009 Financial Results and Financial Outlook
11. Boston Scientific Announces European Approval and First Implants of New Defibrillation Lead System Designed to Simplify the Surgical Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: